The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Open accessAbstract
Multiple myeloma is a genetically complex and heterogenous malignancy with a 5-year survival rate of approximately 60%. Despite advances in therapy, patients experience cycles of remission and relapse, with each successive line of therapy associated with poorer outcomes; therefore, therapies with different mechanisms of action against new myeloma antigens are needed. G protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as a novel therapeutic target for the treatment of multiple myeloma. We review the biology and target validation of GPRC5D, and clinical data from early phase trials of GPRC5D-targeting bispecific antibodies, talquetamab and forimtamig, and chimeric antigen receptor T cell (CAR-T) therapies, MCARH109, OriCAR-017, and BMS-986393. In addition to adverse events (AEs) associated with T-cell-redirection therapies irrespective of target, a consistent pattern of dermatologic and oral AEs has been reported across several trials of GPRC5D-targeting bispecific antibodies, as well as rare cerebellar events with CAR-T therapy. Additional studies are needed to understand the underlying mechanisms involved in the development of skin- and oral-related toxicities. We review the strategies that have been used to manage these GPRC5D-related toxicities. Preliminary efficacy data showed overall response rates for GPRC5D-targeting T-cell-redirecting therapies were ≥64%; most responders achieved a very good partial response or better. Pharmacokinetics/pharmacodynamics showed that these therapies led to cytokine release and T-cell activation. In conclusion, results from early phase trials of GPRC5D-targeting T-cell-redirecting agents have shown promising efficacy and manageable safety profiles, including lower infection rates compared with B-cell maturation antigen- and Fc receptor-like protein 5-targeting bispecific antibodies. Further clinical trials, including those investigating GPRC5D-targeting T-cell-redirecting agents in combination with other anti-myeloma therapies and with different treatment modalities, may help to elucidate the future optimal treatment regimen and sequence for patients with multiple myeloma and improve survival outcomes. Video Summary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although anti-BCMA therapies are approved and have shown clinical benefit for patients with relapsed or refractory multiple myeloma,4–7 relapses continue; thus, there is a need for novel therapies to expand treatment options.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · cited 1×
“…T-cell – redirecting bispe-ci fi c antibodies compared with trials of BCMA-and Fc receptor-like protein 5 – targeting bispeci fi c antibodies [58 – 61], which may be due to the more limited expression pro fi le of GPRC5D in the immune compartment compared with the expression pro fi les of…”
Self-citationDiagnosis and Management of Multiple Myeloma: A Review
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L. A., Tuazon, S., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,029 · cited 1×
“MM can affect multiple organ systems, leading to fatigue, pain, breath-lessness, and mobility issues, as well as neurological effects (including numbness/tingling), renal impairment, bone disease, blood disorders, and frequent infections [7 – 13].”
BackgroundRecent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852 · cited 2×
“3B) [51].”
BackgroundMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789 · cited 1×
“…fi c antibodies, and chimeric antigen receptor T-cell (CAR-T) therapies, patients experience cycles of remission and relapse; with each new line of therapy (LOT), the risk of discontinuation increases due to poor ef fi cacy, accumulating toxicities, and increasingly prevalent comorbidities [15 – 17].”
BackgroundTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744 · cited 8×
“It is unknown whether dysgeusia is a direct on-target, off-tumor effect because GPRC5D immunoreactivity in salivary glands is limited to resident plasma cells, and while GPRC5D is also expressed on fi liform papillae, they are not responsible for taste [25, 41].”
BackgroundInfluentialSelf-citationGlobal Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490 · cited 1×
“Bispeci fi c antibodies can have different constructs, including single-chain variable fragments (scFv), which do not include an Fc domain, and full-size antibody constructs generated through methods, such as Fab-arm exchange [37, 38].”
MethodSelf-citation
Cited by
GPCR drug discovery: new agents, targets and indications
Lorente, J. S., Sokolov, A. V., Ferguson, G., Schiöth, H. B., Hauser, A. S., & Gloriam, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01139-y · Cited by 251
Chari, A., Touzeau, C., Schinke, C., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Morillo, D., Martinez-Chamorro, C., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00385-5 · Cited by 116
Self-citationCAR-T cell therapy in Multiple Myeloma: current status and future challenges
Swan, D., Madduri, D., & Hocking, J. S. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01191-8 · Cited by 121
Bispecific antibodies in the treatment of multiple myeloma
Devasia, A. J., Chari, A., & Lancman, G. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01139-y · Cited by 116
“G protein coupled receptor family C group 5 member D (GPRC5D) GPRC5D is a novel target for myeloma immunotherapy identi fi ed relatively recently [33 – 35].”
BackgroundSelf-citationDhakal, B., Akhtar, O. S., Fandrei, D., Jensen, A. M., Banerjee, R. K., Pan, D., Richard, S., Friend, R. N., Rees, M. J., Costello, P., et al. (2025) · Blood · doi:10.1182/blood.2025029773 · Cited by 49
Metadata
- Authors
- Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., Heuck, C., Kane, C., Verona, R., Moreau, P., Bahlis, N., & Chari, A.
- Affiliations
- Janssen Scientific Affairs (United States) (US)
- Janssen Research & Development (United States) (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- University of Calgary (CA)
- Icahn School of Medicine at Mount Sinai (US)
- ORCID
- Venue
- Blood Cancer Journal
- Published
- 2024-02-02
- Volume
- 14
- Issue
- 1
- Pages
- 24-24
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC10837198
- OpenAlex
- W4391482982
- Cited by
- 113
- References
- 62
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 30
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-03-06)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- GPRC5D, multiple myeloma, talquetamab, bispecific antibodies, CAR T-cell therapy, T cell redirection, skin toxicity, oral toxicity, cerebellar toxicity, cytokine production, pharmacokinetics, pharmacodynamics, treatment efficacy
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Multiple Myeloma, Neoplasm Recurrence, Local, Immunotherapy, Adoptive, Antibodies, Bispecific, Receptors, G-Protein-Coupled
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. https://app.cochat.ai/papers/10.1038/s41408-023-00966-9
- The paper
- Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., Heuck, C., Kane, C., Verona, R., Moreau, P., Bahlis, N., & Chari, A. (2024). GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer Journal. https://doi.org/10.1038/s41408-023-00966-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.